Table 3.

Analysis of dosimetric parameters, changes in CTP classification and the occurrence of hepatic adverse reactions in 74 HCC patients

Dosimetric parameters	Changes in CTP classification		P-value	Hepatic adverse reactions		P-value
	No	Yes		Grades 0–1	Grades 2–3
GTV (mL)	32.83±27.98	25.93±26.13	0.510	32.82±28.84	28.62±22.19	0.623
Total liver volume (mL)	1,297.11±263.19	1,216.67±345.72	0.729	1,327.79±273.34	1,131.31±194.03	0.016
Normal liver volume (mL)	1,246.97±255.86	1,217.35±353.27	0.768	1,277.22±265.37	1,086.82±208.44	0.018
V5 (%)	61.23±21.30	56.36±24.31	0.549	60.01±21.50	63.96±22.15	0.552
V10 (%)	35.04±18.65	32.12±18.20	0.576	35.15±18.64	37.80±18.51	0.642
V15 (%)	22.00±13.88	18.87±12.02	0.543	21.35±13.69	23.18±13.94	0.664
V20 (%)	14.41±9.39	12.88±8.60	0.662	13.86±9.03	16.04±10.51	0.445
V25 (%)	10.25±6.95	9.23±6.37	0.695	9.90±6.85	11.25±7.09	0.524
V30 (%)	7.56±5.43	6.62±4.83	0.642	7.39±5.49	7.81±4.86	0.800

Note: V₅, V₁₀, V₁₅, V₂₀, V₂₅, and V₃₀ indicate detailed dosimetric parameters involving the percentage of normal liver volume receiving 5, 10, 15, 20, 25, and 30 Gy, respectively.

Abbreviations: CTP, Child–Turcotte–Pugh; GTV, gross tumor volume; HCC, hepatocellular carcinoma.